Do analysts recommend CBLL or INGN?

CeriBell currently has a consensus target price of $22.20, suggesting a potential upside of 11.00%. Given CeriBell's stronger consensus rating and higher possible upside, equities research analysts plainly believe CeriBell is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CeriBell 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, CBLL or INGN?

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 8.52 -$53.41M -$1.63 N/A Inogen $351.50M 0.51 -$22.75M -$0.91 N/A

Is CBLL or INGN more profitable?

Inogen has a net margin of -7.08% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -12.90% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Inogen -7.08% -12.90% -8.27%

Does the media refer more to CBLL or INGN?

In the previous week, CeriBell had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for CeriBell and 3 mentions for Inogen. Inogen's average media sentiment score of 0.96 beat CeriBell's score of 0.96 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SGP or INGN?

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 131.12%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Spyglass Pharma is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyglass Pharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer INGN or BBNX?

Beta Bionics has a consensus price target of $19.70, suggesting a potential upside of 17.96%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts clearly believe Beta Bionics is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Beta Bionics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.64

Which has higher earnings & valuation, INGN or BBNX?

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $351.50M 0.51 -$22.75M -$0.91 N/A Beta Bionics $100.25M 7.42 -$73.20M -$1.51 N/A

Is INGN or BBNX more profitable?

Inogen has a net margin of -7.08% compared to Beta Bionics' net margin of -60.27%. Inogen's return on equity of -12.90% beat Beta Bionics' return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% Beta Bionics -60.27% -23.00% -20.55%

Does the media refer more to INGN or BBNX?

In the previous week, Beta Bionics had 9 more articles in the media than Inogen. MarketBeat recorded 12 mentions for Beta Bionics and 3 mentions for Inogen. Inogen's average media sentiment score of 0.96 beat Beta Bionics' score of -0.04 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INGN or TCMD?

Tactile Systems Technology has a consensus target price of $38.60, indicating a potential upside of 25.94%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tactile Systems Technology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86

Does the media prefer INGN or TCMD?

In the previous week, Inogen had 1 more articles in the media than Tactile Systems Technology. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Tactile Systems Technology. Inogen's average media sentiment score of 0.96 beat Tactile Systems Technology's score of 0.96 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tactile Systems Technology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate INGN or BWAY?

Brainsway has a consensus target price of $16.00, indicating a potential upside of 4.64%. Given Brainsway's stronger consensus rating and higher probable upside, analysts clearly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Brainsway 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has higher earnings & valuation, INGN or BWAY?

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $351.50M 0.51 -$22.75M -$0.91 N/A Brainsway $52.22M 11.75 $7.57M $0.35 43.69

Is INGN or BWAY more profitable?

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -7.08%. Brainsway's return on equity of 12.28% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -7.08% -12.90% -8.27% Brainsway 15.68% 12.28% 7.75%

Does the media refer more to INGN or BWAY?

In the previous week, Inogen and Inogen both had 3 articles in the media. Brainsway's average media sentiment score of 1.10 beat Inogen's score of 0.96 indicating that Brainsway is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inogen (INGN) Competitors

$6.65 +0.20 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$6.66 +0.00 (+0.08%)

As of 05:33 PM Eastern

Compare

INGN vs. CBLL, SGP, BBNX, TCMD, and BWAY

Should you buy Inogen stock or one of its competitors? MarketBeat compares Inogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inogen include CeriBell (CBLL), Spyglass Pharma (SGP), Beta Bionics (BBNX), Tactile Systems Technology (TCMD), and Brainsway (BWAY). These companies are all part of the "medical equipment" industry.

How does Inogen compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

89.9% of Inogen shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 2.5% of Inogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inogen has a net margin of -7.08% compared to CeriBell's net margin of -63.51%. Inogen's return on equity of -12.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Inogen	-7.08%	-12.90%	-8.27%

CeriBell has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Inogen has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

In the previous week, CeriBell had 2 more articles in the media than Inogen. MarketBeat recorded 5 mentions for CeriBell and 3 mentions for Inogen. Inogen's average media sentiment score of 0.96 beat CeriBell's score of 0.96 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inogen has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	8.52	-$53.41M	-$1.63	N/A
Inogen	$351.50M	0.51	-$22.75M	-$0.91	N/A

CeriBell currently has a consensus target price of $22.20, suggesting a potential upside of 11.00%. Given CeriBell's stronger consensus rating and higher possible upside, equities research analysts plainly believe CeriBell is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Inogen beats CeriBell on 10 of the 16 factors compared between the two stocks.

How does Inogen compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Inogen (NASDAQ:INGN) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Spyglass Pharma has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	-$6.41	N/A
Inogen	$351.50M	0.51	-$22.75M	-$0.91	N/A

In the previous week, Inogen had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for Inogen and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Inogen's score of 0.96 indicating that Spyglass Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Inogen	Positive

Spyglass Pharma currently has a consensus target price of $45.00, indicating a potential upside of 131.12%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Spyglass Pharma is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

89.9% of Inogen shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Spyglass Pharma has a net margin of 0.00% compared to Inogen's net margin of -7.08%. Spyglass Pharma's return on equity of 0.00% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Inogen	-7.08%	-12.90%	-8.27%

Summary

Spyglass Pharma beats Inogen on 8 of the 14 factors compared between the two stocks.

How does Inogen compare to Beta Bionics?

Inogen (NASDAQ:INGN) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

89.9% of Inogen shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 5.3% of Beta Bionics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Inogen has a net margin of -7.08% compared to Beta Bionics' net margin of -60.27%. Inogen's return on equity of -12.90% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
Beta Bionics	-60.27%	-23.00%	-20.55%

Beta Bionics has a consensus price target of $19.70, suggesting a potential upside of 17.96%. Given Beta Bionics' stronger consensus rating and higher probable upside, analysts clearly believe Beta Bionics is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

In the previous week, Beta Bionics had 9 more articles in the media than Inogen. MarketBeat recorded 12 mentions for Beta Bionics and 3 mentions for Inogen. Inogen's average media sentiment score of 0.96 beat Beta Bionics' score of -0.04 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inogen has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the broader market.

Inogen has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$351.50M	0.51	-$22.75M	-$0.91	N/A
Beta Bionics	$100.25M	7.42	-$73.20M	-$1.51	N/A

Summary

Inogen beats Beta Bionics on 9 of the 16 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Inogen (NASDAQ:INGN) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Tactile Systems Technology has a net margin of 5.91% compared to Inogen's net margin of -7.08%. Tactile Systems Technology's return on equity of 9.70% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
Tactile Systems Technology	5.91%	9.70%	7.53%

Inogen has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Inogen had 1 more articles in the media than Tactile Systems Technology. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Tactile Systems Technology. Inogen's average media sentiment score of 0.96 beat Tactile Systems Technology's score of 0.96 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tactile Systems Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of Inogen shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tactile Systems Technology has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$351.50M	0.51	-$22.75M	-$0.91	N/A
Tactile Systems Technology	$329.52M	2.10	$19.09M	$0.88	34.83

Tactile Systems Technology has a consensus target price of $38.60, indicating a potential upside of 25.94%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Tactile Systems Technology beats Inogen on 10 of the 16 factors compared between the two stocks.

How does Inogen compare to Brainsway?

Inogen (NASDAQ:INGN) and Brainsway (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Inogen and Inogen both had 3 articles in the media. Brainsway's average media sentiment score of 1.10 beat Inogen's score of 0.96 indicating that Brainsway is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a net margin of 15.68% compared to Inogen's net margin of -7.08%. Brainsway's return on equity of 12.28% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-7.08%	-12.90%	-8.27%
Brainsway	15.68%	12.28%	7.75%

Inogen has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Brainsway has a consensus target price of $16.00, indicating a potential upside of 4.64%. Given Brainsway's stronger consensus rating and higher probable upside, analysts clearly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

89.9% of Inogen shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 19.0% of Brainsway shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$351.50M	0.51	-$22.75M	-$0.91	N/A
Brainsway	$52.22M	11.75	$7.57M	$0.35	43.69

Summary

Brainsway beats Inogen on 12 of the 16 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$180.05M	$7.35B	$6.79B	$12.53B
Dividend Yield	N/A	1.25%	2.66%	6.15%
P/E Ratio	-7.31	50.10	27.46	25.27
Price / Sales	0.51	81.68	582.87	119.23
Price / Cash	N/A	26.23	48.53	58.59
Price / Book	0.94	7.41	10.95	6.61
Net Income	-$22.75M	$159.19M	$3.57B	$336.83M
7 Day Performance	-1.63%	0.91%	2.58%	2.52%
1 Month Performance	9.20%	-3.48%	1.67%	0.44%
1 Year Performance	-6.34%	3.80%	35.96%	29.40%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	2.2183 of 5 stars	$6.65 +3.1%	N/A	-8.3%	$180.05M	$351.50M	N/A	1,030	News Coverage
CBLL CeriBell	1.8291 of 5 stars	$18.18 +0.8%	$22.20 +22.1%	+3.8%	$684.11M	$95.07M	N/A	N/A	Positive News Analyst Upgrade Insider Trade
SGP Spyglass Pharma	2.7372 of 5 stars	$19.34 +3.4%	$45.00 +132.7%	N/A	$646.59M	N/A	N/A	65	Positive News
BBNX Beta Bionics	2.6587 of 5 stars	$13.70 -1.3%	$19.70 +43.8%	+7.6%	$618.52M	$100.25M	N/A	294
TCMD Tactile Systems Technology	3.9635 of 5 stars	$26.22 -1.5%	$38.60 +47.2%	+193.7%	$600.45M	$329.52M	29.80	1,086

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors